Time-updated Fibroblast Growth Factor 23 Is Predictive for Posttransplant Diabetes Mellitus in Kidney Transplant Recipients.

IF 3 Q2 ENDOCRINOLOGY & METABOLISM Journal of the Endocrine Society Pub Date : 2024-04-04 eCollection Date: 2024-03-12 DOI:10.1210/jendso/bvae055

Amarens van der Vaart, Daan Kremer, Tessa Niekolaas, Stephan J L Bakker, Peter R van Dijk, Martin H de Borst

{"title":"Time-updated Fibroblast Growth Factor 23 Is Predictive for Posttransplant Diabetes Mellitus in Kidney Transplant Recipients.","authors":"Amarens van der Vaart, Daan Kremer, Tessa Niekolaas, Stephan J L Bakker, Peter R van Dijk, Martin H de Borst","doi":"10.1210/jendso/bvae055","DOIUrl":null,"url":null,"abstract":"Objective: This work aimed to study whether fibroblast growth factor 23 (FGF23) is predictive for incident posttransplant diabetes mellitus (PTDM) in kidney transplant recipients (KTRs).Methods: We repeatedly analyzed plasma C-terminal FGF23 concentrations in 170 KTRs enrolled in the TransplantLines Biobank and Cohort Study. Associations of time-updated plasma FGF23 with incident PTDM were studied by Cox regression.Results: A total of 170 KTRs (46% female, aged 54.4 ± 12.4 years) with 540 FGF23 measurements were included. Plasma FGF23 concentrations at transplantation were 31.1 (0.76-2576) pmol/L. During a follow-up of 24 (12-24) months, 38 patients developed PTDM. The highest FGF23 tertile (compared to the lowest) was associated with an increased risk for PTDM (fully adjusted hazard ratio 20.9; 95% CI, 3.4-130.0; P < .001).Conclusion: In KTRs without diabetes at baseline, the highest tertile of FGF23, compared to the lowest, is predictive for development of PTDM.","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"8 5","pages":"bvae055"},"PeriodicalIF":3.0000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10993900/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Endocrine Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jendso/bvae055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This work aimed to study whether fibroblast growth factor 23 (FGF23) is predictive for incident posttransplant diabetes mellitus (PTDM) in kidney transplant recipients (KTRs).

Methods: We repeatedly analyzed plasma C-terminal FGF23 concentrations in 170 KTRs enrolled in the TransplantLines Biobank and Cohort Study. Associations of time-updated plasma FGF23 with incident PTDM were studied by Cox regression.

Results: A total of 170 KTRs (46% female, aged 54.4 ± 12.4 years) with 540 FGF23 measurements were included. Plasma FGF23 concentrations at transplantation were 31.1 (0.76-2576) pmol/L. During a follow-up of 24 (12-24) months, 38 patients developed PTDM. The highest FGF23 tertile (compared to the lowest) was associated with an increased risk for PTDM (fully adjusted hazard ratio 20.9; 95% CI, 3.4-130.0; P < .001).

Conclusion: In KTRs without diabetes at baseline, the highest tertile of FGF23, compared to the lowest, is predictive for development of PTDM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

时间更新的成纤维细胞生长因子 23 可预测肾移植受者移植后糖尿病的发生。

目的本研究旨在探讨成纤维细胞生长因子 23 (FGF23) 是否可预测肾移植受者 (KTR) 移植后糖尿病 (PTDM) 的发生：我们反复分析了参加 TransplantLines 生物库和队列研究的 170 名 KTR 的血浆 C 端 FGF23 浓度。通过 Cox 回归研究了时间更新的血浆 FGF23 与 PTDM 事件的相关性：结果：共纳入 170 名 KTR（46% 为女性，年龄为 54.4 ± 12.4 岁），测量了 540 次 FGF23。移植时的血浆 FGF23 浓度为 31.1 (0.76-2576) pmol/L。在24（12-24）个月的随访期间，38名患者出现了PTDM。FGF23最高三分位数（与最低三分位数相比）与PTDM风险增加有关（完全调整危险比20.9；95% CI，3.4-130.0；P < .001）：结论：在基线没有糖尿病的 KTR 中，FGF23 的最高三分位数与最低三分位数相比，可预测 PTDM 的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊